Home | K36tx
WEBChanging the treatment landscape for multiple myeloma patients. Learn more. Our Clinical Trial. is now open! Learn More. Our Work. K36’s lead candidate is KTX-1001, a first-in-class, selective inhibitor of the histone methyltransferase (HMT) MMSET, which is overexpressed in up to 20% of multiple myeloma patients due to the t (4;14) translocation.
K36 Therapeutics Launches with $30 Million Series A Financing …
WEBCAMBRIDGE, Mass., Dec. 9, 2021 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held biotechnology company developing breakthrough therapies for the unmet medical needs of cancer...
K36 Therapeutics announces dosing of first patient in KTX-1001 …
WEBK36 Therapeutics. Apr 11, 2023, 08:00 ET. Share this article. KTX-1001 is the first inhibitor of multiple myeloma SET domain (MMSET) to enter clinical development. MMSET is the oncogenic driver...
K36 Therapeutics Announces $70 Million Series B Financing to …
WEBCAMBRIDGE, Mass., June 28, 2023 /PRNewswire/ -- K36 Therapeutics ("K36"), a privately held clinical-stage biotech company developing KTX-1001, an investigational small molecule methyltransferase...
News & Events | K36tx
WEBNov 8, 2023 · Latest News. December 4, 2023. K36 Therapeutics Announces Presentation on KTX-1001 for Relapsed and Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting. Poster to be presented Sunday, December 10, 2023. November 15, 2023.
K36 Therapeutics Named “Overall BioPharma Startup of the Year” …
WEBCAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- K36 Therapeutics (“K36”) has been selected as “Overall BioPharma Startup of the Year” in the third annual BioTech Breakthrough Awards Program...
K36 emerges with $30M to bankroll multiple myeloma drug in …
WEBDec 9, 2021 · K36 Therapeutics has come out of the gates with $30 million in venture funding to back a small-molecule oral treatment from Novartis. The Cambridge, Massachusetts, biotech emerged Thursday to...
K36 Therapeutics Announces FDA Clearance of Investigational ... - BioSpace
WEBCAMBRIDGE, Mass., Aug. 23, 2022 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held biotechnology company developing novel targeted therapies for the unmet medical needs of cancer patients, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application for the …
K36 Therapeutics Named “Overall BioPharma Startup of the
WEBCAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- K36 Therapeutics (“K36”) has been selected as “Overall BioPharma Startup of the Year” in the third annual BioTech Breakthrough Awards Program...
K36 Therapeutics - Crunchbase Company Profile & Funding
WEBAbout. K36 Therapeutics translate epigenetic modulation of oncogenic pathways into small molecule therapies. Cambridge, Massachusetts, United States. 11-50. Series B. Private. www.k36tx.com. 24,693. Highlights. Total Funding Amount. Unlock for free. Contacts 5. Employee Profiles 2. Investors 5. Similar Companies 8. Company Insights.
Skip to content